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A B S T R A C TObjectives: There is a need for a brief symptom index for advanced
kidney cancer that includes perspectives of both patients and clini-
cians and is consistent with the Food and Drug Administration’s
guidance for patient-reported outcome measures. This study devel-
oped and examined the preliminary reliability and validity of the new
National Comprehensive Cancer Network/Functional Assessment of
Cancer Therapy (FACT)-Kidney Symptom Index 19. Methods: Fifty
patients with advanced kidney cancer provided open-ended and
survey responses ranking their most important symptoms. Responses
were reconciled with published clinician reports of the most impor-
tant symptoms. Ten experienced oncologists rated symptoms as
disease- or treatment-related. Patients completed quality-of-life and
performance status measures. Results: A 19-item index was produced
from symptoms that were rated as most important by patients or
clinicians. It includes three subscales: disease-related symptoms (DRS),
treatment side effects (TSE), and general function and well-being (FWB).see front matter Copyright & 2013, International S
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chigan Avenue, Suite 2700, Chicago, IL 60611, USAInternal consistency was good for the full instrument (α ¼ 0.83), the DRS
subscale (α ¼ 0.76), and the FWB subscale (α ¼ 0.78) but lower for the TSE
subscale (α ¼ 0.59). Convergent validity was demonstrated through
correlations with the FACT-General. Patients with differing performance
status were distinguished by the total score (F2,47 ¼ 17.37; Po .0001), the
DRS subscale (F2,47 ¼ 14.22; P o .0001), and the FWB subscale (F2,47 ¼
13.40; P o .0001) but not the TSE subscale (F2,47 ¼1.48; P ¼ 0.2380).
Conclusions: The National Comprehensive Cancer Network/FACT-Kid-
ney Symptom Index 19 combines symptoms deemed most important
by patients and clinicians. Preliminary evidence suggests that the total
score and DRS and FWB subscales are reliable and valid as summary
indexes. The TSE subscale may be least relevant given the advent of
newer therapies.
Keywords: cancer, patient-reported outcomes, quality of life, symptoms.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Every year in the United States, there are 64,770 new cases of
kidney cancer, and an estimated 13,570 deaths [1]. Almost twice as
many men than women are affected, with it representing about
5% of all new cancer diagnoses in men [1]. Approximately 25% to
30% of individuals with kidney cancer are diagnosed with meta-
static disease [2]. For those treated for local disease, about 25%
recur, typically with distant metastases [3]. Surgery is the primary
treatment for early stage disease. Relative 5-year survival rates are
signiﬁcantly worse for distant (11%) and regional (63%) disease
when compared with local disease (91%) [1]. Prior to 2005, the only
available systemic treatment options for metastatic disease were
cytokines, such as interleukin-2 and interferon-alpha. Since that
time, several molecular-targeted therapies have been approved bythe Food and Drug Administration (FDA) for metastatic kidney
cancer, including sorafenib (Nexavar), sunitinib (Sutent), temsir-
olimus (Torisel), everolimus (Aﬁnitor), bevacizumab (Avastin),
pazopanib (Votrient), and axitinib (Inlyta) [4]. Newer targeted
therapies offer promise for improved clinical outcomes [5]; how-
ever, cure remains an elusive goal [6].
Evaluating the clinical beneﬁt of kidney cancer treatment must
include an appreciation for health-related quality of life (HRQOL),
including symptoms of disease and their impact on functioning and
life enjoyment. Systemic therapies used for advanced disease con-
tribute to declines in HRQOL. As patients are presented with second-
and third-line treatment options, HRQOL associated with these
options can be a useful guide when making treatment decisions
[7]. Several HRQOL instruments have been used in kidney cancer
research, including the EuroQoL ﬁve-dimensional questionnaire[8],ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire C30 [10], the Renal Cell Carcinoma
Symptom Index [11], and the Functional Assessment of Cancer
Therapy (FACT)-Kidney Symptom Index (FKSI) [12]. The FKSI was
developed by using both patient and clinician input about the most
important symptoms to assess during drug therapy for advanced
kidney cancer. The 15-item instrument has demonstrated good
internal consistency, test-retest reliability, convergent and discrim-
inant validity, and responsiveness to change in clinical status [12]. It
has been used as the primary patient-reported outcomemeasure for
kidney cancer trials [13,14]. To reduce patient burden, a 10-item
reliable and valid version of the FKSI was used in trials [12,14]. In an
attempt to isolate disease-related symptoms, a 9-item subset of
disease-related symptoms (DRS) was drawn from the FKSI-15 by a
panel of clinical experts [15]. This DRS, also with good reliability and
validity [12], was included as an outcome in clinical trials (e.g.,
[13,16]).
The iterative development of these brief, symptom-focused
indexes occurred prior to the FDA’s Guidance for Industry: Patient-
Reported Outcome Measures: Use in Medical Product Development to
Support Labeling Claims [17]. Consequently, they do not explicitly
ensure content validity in a manner consistent with the Guidance.
For example, although the FKSI-15 development did use patient
input for item generation and review for clarity and readability,
this does not strictly meet the recommendation of the FDA
Guidance, which identiﬁes the centrality of patient involvement
in ﬁnal selection and content through qualitative research meth-
odology. The Guidance also emphasizes reaching saturation in
item generation. A more explicit open-ended questioning, prior
to presenting a list of previously identiﬁed items, might help
ensure that an instrument would meet this requirement.
The National Comprehensive Cancer Network (NCCN)
embarked on an effort to develop and validate symptom indexes
for advanced cancer treatment by using a methodology [7] that
includes both patient and expert clinician input regarding relevant
symptoms with an emphasis on the patient’s perspective. Con-
sequently, we developed the NCCN/FACT-Kidney Symptom Index
(NFKSI) for advanced kidney cancer in accordance with the FDA
Guidance, and examined its preliminary reliability and validity.Methods
The present study was part of a larger study that sought to
develop 11 symptom indexes for different types of advanced
cancer by using a multistep process [7]. First, patients with
advanced kidney cancer answered open-ended questions to
identify their highest priority cancer symptoms. Next, patients’
responses were combined with results from previous surveys of
oncology clinicians to create a symptom index including the most
important patient- and oncology clinician-rated symptoms spe-
ciﬁc to advanced kidney cancer. Next, expert oncologists rated
the identiﬁed symptoms as predominantly disease- or treatment-
related. This was used to create subscales within the measure.
Finally, initial validation analyses were conducted on data col-
lected from patients.
Patient Participants
Adult patients with stage III or IV kidney cancer receiving care at one
of four NCCN member institutions or a community cancer support
organization in 2005 and 2006 were eligible for participation. Partic-
ipants had received at least two cycles of chemotherapy or 1 month
of noncyclical chemotherapy to ensure that patients would have
some experience with treatment-related symptoms and had no other
primary malignancy (excluding nonmelanoma skin cancer) in theprevious 5 years. NCCN accrual sites included Duke Comprehensive
Cancer Center in Durham, NC; Robert H. Lurie Comprehensive Cancer
Center of Northwestern University in Chicago, IL; H. Lee Mofﬁtt
Cancer Center & Research Institution in Tampa, FL; Fred Hutchinson
Cancer Research Center/Seattle Cancer Care Alliance in Seattle, WA;
and NorthShore University Health System in Evanston, IL, which at
the time was afﬁliated with the Robert H. Lurie Comprehensive
Cancer Center of Northwestern University. A private, nonproﬁt social
service organization, Cancer Wellness Center of Northbrook, IL, also
served as an accrual site. All participants as judged by their treating
physician and study staff had sufﬁcient cognitive ability to provide
informed consent and were ﬂuent in reading and speaking English.
All participants provided informed consent in accordance with
institutional review board and Health Insurance Portability and
Accountability Act (HIPAA) guidelines prior to participating and
completed all measures at one time point. Participants received $50
in exchange for their participation.
Patient Procedures
After providing basic demographic information, patients com-
pleted a two-part survey. First, patients were asked to “Please
think of the full range of your experience receiving drug treatment
for your illness. Please tell me what you think are the most
important symptoms or concerns to monitor when assessing the
value of drug treatment for your illness.” This open-ended prompt
was intended to identify concepts not currently included in the
Kidney Cancer Symptom/Concern Checklist (Checklist). Patients
were asked to rate each of the identiﬁed symptoms on a scale
from 0 (not important to you) to 10 (extremely important to you).
Second, patients were provided the Checklist and asked to
identify the 10 most important symptoms and write in additional
symptoms. Then, patients were asked to reduce their list of top 10
symptoms down to the 5 “very most important” symptoms. The
Kidney Cancer Symptom/Concern Checklist [12,18] consists of 26
symptoms identiﬁed by expert clinicians to be related to cancer in
general and speciﬁc to kidney cancer. To control for potential
response bias due to item order, four versions of the Checklist
presenting symptoms in different order were administered.
Patients next completed the FACT-General (FACT-G) [19] and
the FKSI-15 [12] with duplicate items administered only once. The
FACT-G total and subscales (Physical Well-being [PWB], Func-
tional Well-being [FWB], Emotional Well-being [EWB], and Social
Well-being [SWB]) were used in analyses. Higher scores on all
FACT instruments indicate better QOL. Patients completed the
Eastern Cooperative Oncology Group Performance Status (ECOG-
PS) [20], which assesses performance as fully ambulatory without
symptoms (0), fully ambulatory with some symptoms (1), requir-
ing less than 50% of awake time to rest (2), requiring more than
50% of awake time to rest (3), or bedridden (4).
Analysis of Patient Data
Frequency distributions were analyzed from the patient-generated
symptom list. Symptoms/concerns that were identiﬁed by at least
10% of the sample were retained for further consideration. If a
treatment-related symptom was identiﬁed by 20% or more of the
patients, it was retained in the ﬁnal instrument. Identiﬁed symp-
toms were analyzed to determine whether they were already
represented on the Checklist. If not, they were reviewed further to
select an item from the Functional Assessment of Chronic Illness
Therapy (FACIT) measurement system to include in the ﬁnal
instrument. FACIT items were used where the patient-generated
content matched an existing item because they had already been
tested for comprehension, validity, and translatability.
Frequency distributions of patients’ ﬁve most important Check-
list symptoms/concerns were created. A “write-in” symptom was
Table 1 – Sociodemographic characteristics of study
participants.
Characteristics % (N ¼ 50)
Mean age  SD (y) 59.4  10.5
Gender
Female 36
Male 64
Race/ethnicity
African American 6
White 94
Non-Hispanic 96
Highest education
Some high school or less 6
High school graduate or GED 28
Vocational college or some college 22
College degree 26
Professional or graduate degree 18
Current occupational status
Homemaker 2
Unemployed 2
Retired 34
On disability 24
On leave of absence 10
Part-time employed 8
Full-time employed 20
GED, general educational development.
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frequency of chance endorsement of a symptomwas calculated by
dividing 5 (the allowable number of “very most important symp-
toms”) by 26, the number of items in the Checklist, and multi-
plying this by 50 (number of participants). This established a cutoff
threshold. Items that met or exceeded this cutoff were retained for
consideration in the ﬁnal instrument. Items that were within a
point of this cutoff were retained to err on the side of inclusion.
Symptoms that were endorsed at rates well above the cutoff
threshold were evaluated to determine whether an additional
symptom from the same domain merited inclusion.
Archival Data Review
Previously in the development of the FKSI-15 [12], kidney cancer
clinicians rated the most important symptoms to include in a
kidney cancer symptom index. These published rankings were
reviewed by the current study team. Symptoms that had been
identiﬁed in clinicians’ top 10 were retained for possible inclusion
in the new instrument.
Physician Participants and Procedures
Ten oncology physicians were recruited via e-mail with assis-
tance of the NCCN central ofﬁce. All treating physicians at all 21
NCCN member institutions were potentially eligible to partici-
pate. In the case of kidney cancer, there was typically only one
physician at each member institution who met eligibility criteria
(at least 3 years’ experience treating at least 100 patients with
advanced kidney cancer). All physicians provided informed con-
sent in accordance with institutional review board and HIPAA
guidelines and received $100 for their participation.
Physicians completed the Checklist augmented by additional
symptoms (51 total) in an online survey [21]. Physicians rated
each symptom/concern on a ﬁve-point scale: “exclusively dis-
ease-related,” “predominantly disease-related,” “too close to
determine” (or neither disease- nor treatment-related), “predom-
inantly treatment-related,” and “exclusively treatment-related.”
Analysis of Physician Data
Clinicians’ ratings of symptom cause were collapsed into three
categories: exclusively/predominantly disease-related, too close
to determine/neither, and exclusively/predominantly treatment-
related. Items rated in the ﬁrst category by more than half of the
experts were labeled “disease-related symptoms” (DRS); those
rated by more than half of the experts as treatment-related were
labeled “treatment side effects” (TSE). Remaining items were not
symptoms and were therefore classiﬁed as “function/well-being”
(FWB), reﬂecting their underlying general content.
Scale Construction
The NFKSI-19 includes symptoms/concerns that were 1) sponta-
neously generated from patients in open-ended questions, 2)
ranked by patients on the Checklist as most important, or 3) ranked
by clinicians in previous research as being most important to
assess. Items from the FACIT measurement system were selected
to represent each symptom/concern. Higher scores on the NFKSI-19
indicate greater symptom burden. Items were then assigned to a
subscale (TSE, DRS, FWB) on the basis of expert allocation.
Preliminary Reliability and Validity Analyses
Preliminary analyses on NFKSI-19’s reliability and validity were
conducted by analyzing data from items also included in the
FACT-G and FKSI-15 collected for this study. Cronbach’s alpha
assessed the internal consistency reliability of NFKSI-19 total and
subscales. Convergent validity was assessed by examiningSpearman correlations among the NFKSI-19 total and subscales
and the FACT-G total and subscale scores after removing over-
lapping items that would inﬂate the correlation. One-way anal-
yses of variance examined the relationship between ECOG-PS and
NFKSI-19 to assess criterion validity.Results
Participant Characteristics
Fifty patients (mean age ¼ 59.4  10.5 years; range 33–79 years)
participated. Participants were predominantly male (64.0%), White
(94.0%), highly educated (66.0%with greater than high school), and not
working outside of the home (72.0%). Most patients (78.0%) reported
currently experiencing symptoms or requiring daytime rest. Table 1
presents the sociodemographic characteristics of the participants.
The physicians had a mean age of 49.3  5.7 years, and all but
one were male. Years of experience treating advanced kidney
cancer ranged from 6 to more than 20. Sixty percent had treated
more than 500 patients with advanced kidney cancer. The 10
physicians were from nine different institutions.
Symptom Identiﬁcation
Fourteen symptoms were generated by at least 10% of the patients in
response to an open-ended prompt (mean ¼ 4.5  3.7 symptoms
generated per participant; see Table 2). Most common were fatigue
(48%), concern about treatment effectiveness (36%), and nausea
(31%). The symptoms identiﬁed as most important by 42 patients
(eight patients had missing data in this phase) were concern about
treatment effectiveness (mean¼ 9.3), being able to function normally
(mean ¼ 8.4), and weakness (mean ¼ 8.0). In an attempt to be
inclusive, three concerns (ﬁnances, blood pressure, and sleep issues)
identiﬁed just below the cutoff were retained for further review.
Table 2 – Participant-generated symptoms and their perceived importance.
Symptom Rank % of responses
(n ¼ 42)
Mean importance
rating (0–10)
Symptom/concern
in checklist
Fatigue 1 48 6.2 Yes
Treatment effectiveness 2 36 9.3 Yes
Nausea 3 31 6.5 Yes
Side effects 4 24 6.5 Yes
Diarrhea 5 19 7.0 No
Weight loss 6 17 7.1 Yes
Fever 6 17 7.0 Yes
Hair loss 6 17 5.6 No
Appetite 6 17 5.9 Yes
Skin issues 10 14 6.5 No
Taste issues 10 14 5.3 No
Function normally 12 12 8.4 Yes
Pain 12 12 7.0 Yes
Weakness 14 10 8.0 No
Finances 15 7 9.0 No
Blood pressure 15 7 8.7 No
Sleep issues 15 7 7.3 Yes
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 8 9 – 7 9 6792Diarrhea was identiﬁed as a new concept not included on the
Checklist and was within a percentage point of the a priori cutoff.
Given its increasing importance in the era of targeted chemotherapy,Table 3 – Comparison of patient and oncology clin-
ician symptom rankings.
Symptom Patient
overall rank
(% endorsed)
Oncology
clinician
overall rank
Side effects of treatment 1 (52) 2
Lack of energy (fatigue) 2 (42) 2
Fatigue 3 (34) –
Worry that my condition
will get worse
4 (30) –
Being able to enjoy life 5 (28) –
Being able to work
(include work at home)
6 (20) –
Pain 6 (20) 4
I am content with the
quality of my life right
now
8 (18) –
Shortness of breath 8 (18) 7
Nausea 10 (16) 13
Being able to enjoy the
things I usually do for
fun
10 (16) 20
Being able to sleep well 10 (16) 25
Appetite 13 (14) 5
I have bone pain 14 (10) 7
I am losing weight 17 (8) 1
I am bothered by fevers – 5
Because of my physical
condition, having
trouble meeting the
needs of my family
17 (8) 7
I am losing hope in the
ﬁght against my illness
17 (8) 10
Forced to spend time in
bed
20 (6) 10
I have been coughing 20 (6) 10
 Data from Cella et al. [12].it was retained. Other new concepts did not meet the cutoff for
retention of treatment-related symptoms (e.g., hair loss, skin issues,
and taste issues), were considered outside the scope of the HRQOL
concept (e.g., ﬁnancial status or concerns), or were considered to be a
sign (a manifestation of a condition observable by others such as
blood pressure), not a symptom. This resulted in the retention of 11
symptoms for the ﬁnal instrument.
Seven of the 26 symptoms on the Checklist were endorsed by
patients as the most important to monitor at a probability greater
than chance (see Table 3). Two additional items were endorsed
within one point of the cutoff. All these concepts were retained
for the ﬁnal measure. Being able to sleep well was ranked by
patients just below the a priori threshold. Given its mention on
the free response portion of the survey as well as its ranking on
the Checklist, it was retained in the ﬁnal measure. Other
symptoms with equal Checklist ratings included nausea (already
included in the ﬁnal measure) and “Being able to enjoy the things
I usually do for fun.” Because the latter was not mentioned in the
free response results and its concept was covered by the higher
ranked item “Being able to enjoy life,” it was removed from
further consideration. No write-in symptoms met the threshold
for retention; most were cited only by one patient.
Among patients’ top priority symptoms, only four (side effects
of treatment, lack of energy, pain, and shortness of breath) were
rated by clinicians as important at a probability greater than
chance in the FKSI-15 development study (see Table 3) [12]. Three
of the clinician top-priority items were not retained in the ﬁnal
measure. “Losing hope in the ﬁght against my illness” was
considered to be the same concept as the higher ranked “Worry
that my condition will get worse.” Because it was not rated highly
by patients and was not one of the top ﬁve clinician-rated
symptoms, it was omitted. Having trouble meeting the needs of
family because of one’s physical condition and being forced to
spend time in bed were eliminated on the basis of low patient
and expert rankings, and lack of speciﬁcity to kidney cancer.
Item Selection for the NFKSI-19
FACIT items were identiﬁed for the selected patient-generated
and Checklist domains. One rare symptom (“I have had blood in
my urine”) had been included in the FKSI-15 and was retained
because of its importance clinically. This resulted in the inclusion
of 19 items in the NFKSI-19: a 13-item DRS subscale, a 3-item TSE
subscale, and a 3-item FWB subscale (see Table 4).
Table 4 – NFKSI-19 items by subscale across kidney cancer symptom indices.
Subscale Item NFKSI-19 FKSI-15 FKSI-10 FKSI-DRS FACT-G
DRS-P I have a lack of energy √ √ √ √ √
I have pain √ √ √ √ √
I am losing weight √ √ √ √
I feel fatigued √ √ √ √
I have been short of breath √ √ √ √
I am bothered by fevers (episodes of high body
temperature)
√ √ √
I have bone pain √ √ √ √
I have been coughing √ √ √
I feel weak all over √
I have had blood in my urine √ √ √
I have a good appetite √ √ √
I am sleeping well √ √ √
DRS-E I worry that my condition will get worse √ √ √ √
TSE I have nausea √ √
I have diarrhea (diarrhoea) √
I am bothered by side effects of treatment √ √ √ √
FWB I am able to work (include work at home) √ √ √
I am able to enjoy life √ √ √ √
I am content with the quality of my life right
now
√
√
DRS-E, Disease-Related Symptoms-Emotional; DRS-P, Disease-Related Symptoms-Physical; FACT-G, Functional Assessment of Cancer
Therapy-General; FKSI, Functional Assessment of Cancer Therapy-Kidney Symptom Index; FKSI, Functional Assessment of Cancer
Therapy-Kidney Symptom Index; FWB, General Function and Well-Being; NFKSI-19, National Comprehensive Cancer Network/Functional
Assessment of Cancer Therapy-Kidney Symptom Index 19; TSE, Treatment Side Effects.
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Two symptoms (bother by treatment side effects and nausea)
were categorized by clinicians as TSE. Diarrhea was added for
reasons mentioned above [22–24]. Clinicians’ ratings of the
remaining 16 symptoms were reviewed by the senior author (D.
C.) for scale assignment. Three items (able to enjoy life, able to
work, and content with quality of life) were categorized as FWB.
One item (worry that condition will get worse) was considered an
emotional DRS, thus generating a distinction between DRS-P
(physical) and DRS-E (emotional).
Preliminary Reliability and Validity
Two of the ﬁnal NFKSI-19 items were not in the original FACT-G
or FKSI-15 (“I feel weak all over” and “I have diarrhea”; see
Table 4). Therefore, these items were treated as missing, andTable 5 – Spearman correlation coefﬁcients of NFKSI-19 w
where applicable
Instrument/subscale PWB SWB
NFKSI-19 0.76 0.24
P o 0.0001 P ¼ 0.0889
NFKSI-19 DRS 0.75 0.26
P o 0.0001 P ¼ 0.0633
NFKSI-19 TSE 0.61 0.09
P o 0.0001 P ¼ 0.5197
NFKSI-19 FWB 0.52 0.25
P o 0.0001 P ¼ 0.0790
DRS, Disease-Related Symptoms; EWB, Emotional Well-being; FACT-G,
Well-Being; NFKSI-19, National Comprehensive Cancer Network/Function
Physical Well-being; SWB, Social Well-being; TSE, Treatment Side-Effectscores on the NFSKI-19 were prorated according to the FACIT
scoring protocol [25]. Internal consistency reliability for the
NFKSI-19 was good (17 items with data, α ¼ 0.83). While the
DRS subscale (12 items with data, α ¼ 0.76) and the FWB subscale
(α ¼ 0.78) demonstrated adequate international consistency
reliability, the TSE subscale (2 items with data, α ¼ 0.59) displayed
less adequate internal consistency reliability.
Associations between the NFKSI-19 and the FACT-G total and
subscales were evaluated with Spearman correlation coefﬁcients
corrected for overlapping items (see Table 5). The total NFKSI-19
was moderately to strongly correlated with the FACT subscale
and total scores apart from the FACT SWB subscale. The NFKSI-19
DRS showed a similar pattern of correlations. The NFKSI-19 TSE
was correlated only with the PWB subscale (r ¼ 0.61, P o .0001).
The NFKSI-19 FWB was moderately to strongly correlated with
the FACT-G, FACT PWB subscale, and FACT FWB subscaleith FACT-G subscales, corrected for overlapping items
EWB FWB FACT-G
0.41 0.67 0.68
P ¼ 0.0031 P o 0.0001 P o 0.0001
0.42 0.56 0.68
P ¼ 0.0026 P o 0.0001 P o 0.0001
0.26 0.09 0.36
P ¼ 0.0716 P ¼ 0.5410 P ¼ 0.0098
0.33 0.78 0.70
P ¼ 0.0198 P o 0.0001 P o 0.0001
Functional Assessment of Cancer Therapy-General; FWB, Function/
al Assessment of Cancer Therapy- Kidney Symptom Index 19; PWB,
s.
Table 6 – NFKSI-19 score means and SDs by performance status.
ECOG-PS N NFKSI-19 DRS TSE FWB
0 (no symptoms) 11 57.0  9.1 38.4  6.7 8.9  3.5 9.6  2.2
1 (ambulatory with symptoms) 22 53.4  7.3 37.0  4.8 8.6  3.2 7.9  1.8
2 (o50% rest) or 3 (450% rest) 17 39.2  10.4 27.4  7.8 7.1  2.3 5.1  3.1
DRS, Disease-Related Symptoms; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; FWB, General Function and Well-Being;
NFKSI-19, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19; TSE, Treatment
Side Effects.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 8 9 – 7 9 6794(though this was expected as all three NFKSI-19 FWB items are
from the FWB subscale).
The ability of the NFKSI-19 to discriminate between patients’
performance status (ECOG-PS) was analyzed. Because only four
patients reported having a performance status of 3, these
patients were collapsed with category 2. Scores on the NFKSI-19
differed by ECOG-PS in the expected direction (see Table 6), with
higher scores on the NFKSI-19 corresponding to better perform-
ance status. The total NFKSI-19 (F2,47 ¼ 17.37,; P o .0001), DRS
subscale (F2,47¼ 14.22; P o .0001), and FWB subscale (F2,47 ¼ 13.40;
P o .0001) all signiﬁcantly discriminated between the three
categories of performance status. The TSE subscale did not
discriminate performance status scores (F2,47 ¼ 1.48; P ¼ 0.2380).Discussion
The NFKSI-19, a new symptom index that includes symptoms
rated as highest priority from patients with advanced kidney
cancer and experienced clinicians, was developed by using
methods consistent with the FDA’s Guidance [17]. Qualitative data
on symptoms most important to patients were consistent with
previous research, suggesting that fatigue, TSE, and worry about
one’s condition worsening are primary concerns. NFKSI-19 items
offer support for the content validity of previous instruments
(e.g., FKSI-15 and FKSI-DRS). The content of the FKSI-15 was
supplemented with additional symptoms of weakness, nausea,
diarrhea, and contentment with QOL.
It was notable that there was limited overlap between patient
and clinician views on the most important symptoms. Clinicians
rated weight loss as most important [12], yet it ranked 17th
among patients. This discrepancy is consistent with previous
work [26–30]. Clinicians may more readily focus on symptoms
that suggest disease progression or factors that may delay or
reduce treatment (e.g., bone pain and fever), whereas patients
may more readily identify psychosocial symptoms (e.g., worry
and ability to work) as most relevant. In addition, relatively rare
symptoms (e.g., weight loss) that tend to occur late in the disease
course will not be rated as important by patients who have not
experienced it or do not realize that it is an ominous harbinger.
Yet, it is a very important clinical symptom that warrants
inclusion in a priority index for advanced disease. Our experience
in scale construction and these ﬁndings in particular demon-
strate the beneﬁt of including both patient and clinician perspec-
tives to create a fuller understanding of HRQOL in advanced
kidney cancer and provide a more adequate capture of the
perspective of a patient with advanced kidney cancer.
Clinicians’ assessments on the cause of symptoms were con-
sistent with previous work [15]; NFKSI-19 items were able to be
sorted into a 13-item DRS subscale, a 3-item TSE subscale, and a 3-
item FWB subscale. As the NFKSI-19 includes all items from the
FKSI-15, FKSI-10, and FKSI-DRS, it is possible to use the NFKSI-19
and calculate scores for these earlier measures to facilitate analyses
with previously collected data. Because of the inclusion of fouritems on the NFKSI-19 that were not originally part of the FKSI-15, it
is not possible to directly calculate NFKSI-19 scores from the FKSI-
15. However, one can prorate scores from FKSI data to derive scores
comparable to the NFKSI-19 if more than 50% of the 19 NFKSI items
are completed: 19  [(sum of NFKSI item responses)/(number of
NFKSI items completed)] [25]. The NFKSI-19 DRS, TSE, and FWB
subscales offer advantages over other HRQOL instruments; clearly
designated subscales separate clusters of symptoms that may be of
greater interest to patients or clinicians or more relevant for a
speciﬁc clinical research protocol. This is particularly relevant in
kidney cancer considering that seven drugs have been approved by
the FDA for treating metastatic disease since 2007. Whereas it is
unlikely that the symptoms associated with underlying malignancy
or its progression are going to change, the toxicity proﬁle of current
treatments can change rapidly. Hence, future work should develop
strategies to more frequently update treatment-related symptom
scales. NFKSI-19 scores can therefore be reported by subscale.
The NFKSI-19 demonstrates preliminary reliability and val-
idity. The total measure, DRS, and FWB subscales demonstrate
good internal consistency. Only two (of the three) items in the
TSE subscale were tested in this study (I have nausea; I am
bothered by side effects of treatment); the low alpha (0.59) is not
surprising given one item taps a speciﬁc side effect, while the
other asks broadly about side effects. Therefore, any side effects
other than nausea will contribute to responses on one but not the
other question, introducing error. Convergent validity was dem-
onstrated through correlations with the FACT-G total and sub-
scales. The NFSKI-19 is focused on physical and functional
symptoms, and so poor correlations with social well-being were
expected. The NFKSI-19 also demonstrates criterion validity in
distinguishing patients with differing performance status.
Given the overlap among these measures, guidelines for instru-
ment selection may be useful. We recommend the NFKSI-19 when
the goal is focused assessment of symptoms in advanced kidney
cancer. Among the FKSI options (see Table 4), it best ensures
content validity from the perspective of the FDA Guidance [17]. All
other FKSI options are embedded within the NFKSI-19, and could
therefore be scored from the administration of the NFKSI-19. This
was demonstrated by Butt et al. [31] who calculated NFKSI-19 total,
DRS, FKSI-15, and FKSI-DRS-9 norms for the general U.S. adult
population. If a briefer assessment is needed, any of the subordi-
nate versions (FKSI-15, FKSI-10, FKSI-DRS) are valid options.Implications
As the measurement of clinically meaningful patient outcomes in
advanced cancer has evolved, a greater emphasis has been placed
on HRQOL and patient-reported disease-speciﬁc symptoms. As a
result, the development of measures of disease-speciﬁc symp-
toms has become essential to the comprehensive assessment of
HRQOL in clinical trials and practice, particularly with respect to
advanced cancers for which curative options are limited. The
present study extends previous ﬁndings in kidney cancer through
the development and initial validation of a symptom measure
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measurement of disease-speciﬁc HRQOL has the potential to
improve symptom monitoring and intervention, patient satisfac-
tion with treatment, medical decision making, and health policy.
It also provides a foundation for better assessment of the HRQOL
effects of disease versus emerging treatments in kidney cancer.
The NFKSI-19 is the most comprehensive and up-to-date kidney
cancer–speciﬁc instrument available that was developed by using
methods consistent with the FDA’s Guidance [17].Limitations
The study sample was predominantly White and male and
included patients with only advanced kidney cancer. Thus,
generalizability of ﬁndings to earlier stage disease and other
sociodemographic groups is limited. The same 50 patients iden-
tiﬁed NFKSI-19 content and provided initial validation data.
Because of the cross-sectional study design, it was not possible
to assess test-retest reliability or sensitivity to change. Future
research focused on longitudinal data collection in a more
diverse sample is needed for further validation. Moreover, in
contrast to the DRS and FWB subscales, the TSE subscale
demonstrated notably less adequate reliability and validity,
reﬂecting an important area for further research. Finally, it is
likely that because of treatment advances since this data collec-
tion, there is a different proﬁle of high-priority current treatment-
related symptoms. Advantages of the NFKSI-19 are that 1) the
treatment-related symptoms are identiﬁed in their own subscale
allowing for the instrument adaptation over time without affect-
ing the other subscales and 2) the inclusion of the generic item
“I am bothered by side effects of treatment” enables patients to
respond on the basis of their own experience of side effects.
Regardless, it is still likely worthwhile to retest reliability and
validity including an assessment of content validity for any
patient-reported outcome instrument periodically to ensure that
the instrument is still reﬂecting current priority symptoms
because available treatment and supportive care choices may
change. The frequency of retesting should reﬂect the velocity of
change in the treatment landscape.
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